U.S. Markets open in 39 mins.

SIGA Technologies, Inc. (SIGA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.34+0.11 (+3.41%)
At close: 3:28PM EDT
People also watch
  • SIGA up over 2% right now!!
  • SIGA lost ~18% from it high. And still dropping. As usual, it will fade into the abyss, because management doesn't care to promote the stock or put out news or support it in any way. What do they care about the stock price? They pay themselves absurd salaries and just use the stock share bonus plan as their own personal ATM machine.
  • NIH is handing out research $$$. ST-669, 610 still on the back burner, ehhh?
    NIAID Omnibus BAA:
    "Research Area 004: Development of Broad-spectrum Therapeutic Products for Biodefense, Anti-Microbial Resistant Infections and Emerging Infectious Diseases

    The objective of this Research Area is the development of broad-spectrum therapeutic products for use in post-event settings following the intentional release of a NIAID Category A, B, or C Priority Pathogen, zika virus, or in response to naturally-occurring outbreaks of infectious diseases caused by these pathogens.

    Solicited products are anticipated to include: Antibacterial Broad-spectrum Therapeutics; Antiviral Broad-spectrum Therapeutics; and, Anti-toxin Therapeutics."
    Opportunities - Federal Business Opportunities: Opportunities
  • Lassa target wasn't "licensed" and is being developed actively by another private company with recent funding. Siga retained an interest/royalty.
  • What I find interesting is the market maker CDEL has gotten to sell around 12,000shares @&3.60 or higher, and, now they're buying them all back @$3.30 or less. What's with that?
  • Monster MicroCaps Research Alert to SIGA shareholders.
    Clean energy Technologies (CETY) is under 3 pennies with a market cap of close to $4 million and just announced it is expanding operations and marketing by opening Sales & Service Center in Europe to serve the current 65 HRS (Heat Recovery Systems) installations and to expand sales in Europe.

    CETY purchased General Electric Heat Recovery Systems in 2015 and products are now very attractive to huge unmet markets and can achieve over $250 million annual sales within the next 2 to 3 years. Demand for conversion of wasted heat to electrical energy in big applications is very large and unmet!

    Each CETY HRS (Heat Recovery System) sells for about $300,000.

    Shares could yield enormous percentage return on investment.

    Clean Energy Technologies, Inc. Establishes CETY Europe Sales and Service Center
    COSTA MESA, Calif., June 1, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (OTC: CETY) announced today that it has established a new CETY Europe Sales and Service Center in Silea (Treviso), Italy. ...
  • How much does an NDA cost?
  • (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ....GLTA !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • https://www.fbo.gov/index?s=opportunity&mode=form&id=5a9a035b917210ff0025c05226dbdb62&tab=core&_cview=0

    Opportunities - Federal Business Opportunities: Opportunities
  • Okay folks, for what it's worth . . . the listing requirements are all on the NASDAQ site. Best I can tell, there's only one way for SIGA to get back in- the share price has to go over 4$ to satisfy the "Market Value Standard" for listing on the national Global Market. Almost every other Standard requires positive Stockholders' Equity, which SIGA definitely lacks; I can't imagine a waiver of that requirement considering just how negative the number is.
    Soooo . . . everyone quit selling!
    Different topic- SIGA is just a regular example of how corporate America works. It's all mutual back-scratching and overpaid executives and we've been conditioned to accept it. But I do appreciate the subscription that stockholders were offered, and took advantage of it. At least it wasn't an inside cooked deal, which most have been in the past. Considering where SIGA was, $.20 n 12/2415, and where it is now, there really isn't much to complain about. Apparently, someone out there thinks this company is worth a fair amount of money.
    For the record, I've held a large amount of SIGA sock for quite a number of years and have experienced al the frustrations that you would expect from the nonsense the company has put the shareholders through. But the bottom line is that I could have sold at any time, just like anyone else.
  • So rather than enter the fray, I choose to create a new post. I don’t profess to be an expert on the Nasdaq, but I’m interpreting what is provided to me on their website.
    There are three different tiers for securities to be listed on the Nasdaq: the Global Select Market, the Global Market, and the Capital Market. If one goes to https://listingcenter.nasdaq.com/assets/initialguide.pdf and goes to page 8, there is a column called Market Value Standard, which is one of the standards by which a company can initially list on Nasdaq’s Global Market. This standard is, by my reckoning, the only one which SIGA can use without a waiver of some sort. The only criteria of this standard that are not met are the bid price requirement which, according to the footnote, has to be maintained for 90 days, and the market makers requirement, and I know nothing about how that works. I find nothing that states that there is any requirement beyond what is listed in that column to satisfy initial listing. Of course, Nasdaq has the disclaimer that they can refuse listing for any reason they feel appropriate.
    As I said in my earlier post, I can’t imagine getting a waiver for Stockholders’ Equity, as negative as it is. If SIGA can get one it would open up the Global Select Market. That waiver aside, there is only one other Standard, the Total Assets/Total Revenue Standard of the Global Market, which might be used for entry, but it would still require a waiver of the Total Revenue requirement and that’s not likely considering the title of the Standard.
    If there is anything wrong with the factual content in the above, as opposed to my opinion, please educate me.
    Thank you.

  • http://www.nasdaq.com/press-release/bavarian-nordic-announces-notification-of-request-for-proposal-for-freezedried-imvamune-20170616-00060

    Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE - NASDAQ.com
    Sole source request will allow transition toward long-term stockpiling of Bavarian Nordic's smallpox vaccine COPENHAGEN, Denmark, June 16, 2017-.
  • UP 16 cents to DOWN a nickel. What a stock! What a company!! Must be the incredible buy demand!
  • Meanwhile, back at the ranch, SIGA goes down again, two days in a row, about 10% in two days. Not really acting like a stock with high demand, or one that is about to make a great announcement, get relisted, or anything else for that matter. When something good is about to happen, the general population is always the last to know.
  • SIGA looking GREAT as usual. Nasdaq listing in no time at all! Look at all that buying interest!

    Hey Sally, GREAT call on BCLM!!
  • Great stock. High demand. Off the pink sheets for sure very soon. I grew tired the other day and just tried to sell 1K of my remaining pathetic shares for 3.47 all day and no takers. Since the management team isn't reliant on the share price and instead uses the CF as their personal ATM machines with bonuses and raises, why would they care about the share price or do anything to promote the company or stock?!?
  • Are you kidding???? I put a Tiny order in about a month ago for 70shrs @ $3 Flat and The MM's Pulled it out of a nose dive at what?????? $3.01 I Smell Something............
  • Unreal! This company hasn't had a conference call in 2.5 years and there may have been 10 people on it. As far as I know they haven't presented at a investor conference of any kind for 7.5 years (if they ever have), possibly longer. If anyone knows differently please let us all know.

    I expect NDA filing late this year and FDA approval by mid next year. It seems clear that BARDA - CDC and Def. Department intend to continue adding ST-246 to the SNS both in pill and IV form.

    With FDA approval comes 50mm for shelf life extension, an additional 40mm of 100mm total on approval, as well a Priority Review Voucher -- conservatively worth 150mm.

    I also expect international demand from additional countries once their drug gets approval. I would argue that this company has an on going, recurring revenue business not merely a one time business opportunity as these drugs have shelf lives or varying lengths.

    The black swan event here in unimaginable - But a guy named Bill Gates isn't the only one in high places of responsibility doing exactly that -- imagining the consequences. The loss of life could be immense but the economic consequences would be even more dire for the human race.

    One more point -- Am I the only guy who just realized they hired a new Investor Relations firm ? -- Lazar Partners (specializing in healthcare companies).

  • http://www.globenewswire.com/news-release/2017/05/31/1004941/0/en/SIGA-to-Present-at-the-Jefferies-Global-Healthcare-Conference-on-June-9-2017.html

    SIGA to Present at the Jefferies Global Healthcare Conference on June 9, 2017